Table 1.
Demographic and laboratory results of the groups.
| Overt hypothyroid n = 48 |
Subclinical hypothyroid n = 50 |
Euthyroid Hashimoto n = 56 |
Control n = 50 |
P | |
|---|---|---|---|---|---|
| Age (mean ± SD) | 35.79 ± 7.28 | 36.80 ± 8.19 | 36.30 ± 8.11 | 35.42 ± 7.64 | 0.46 |
|
| |||||
| TSH (mIU/mL) | 11.6 [IQR: 7.27–26.2] |
7.25 [IQR: 5.94–8.61] |
2.39 [IQR: 1.66–3.13] |
1.88 [IQR: 1.46–2.5] |
<0.0001 |
|
| |||||
| FT3 (ng/dL) | 2.09 ± 0.37 | 2.99 ± 0.36 | 3.19 ± 0.2 | 3.32 ± 0.43 | <0.0001 |
|
| |||||
| FT4 (ng/dL) | 0.82 [IQR: 0.69–0.89] |
1.08 [IQR: 1.02–1.18] |
1.17 [IQR: 1.07–1.23] |
1.20 [IQR: 1.13–1.34] |
<0.0001 |
|
| |||||
| Total-C (mg/dL) | 228.16 ± 38.91 | 204.5 ± 40.9 | 183.6 ± 31.5 | 176.4 ± 13.6 | <0.0001 |
|
| |||||
| TG (mg/dL) | 138 [IQR: 110–160] |
115 [IQR: 82.7–133.2] |
98.5 [IQR: 76.7–140.7] |
81.50 [IQR: 69.7–110] |
<0.0001 |
|
| |||||
| HDL-C (mg/dL) | 57.10 ± 13.73 | 56.34 ± 12.06 | 56.69 ± 11.66 | 54.68 ± 10.96 | 0.274 |
|
| |||||
| LDL-C (mg/dL) | 144.5 [IQR: 120–166] |
134 [IQR: 110–143] |
116 [IQR: 102–136.7] |
108.5 [IQR: 97.75–117] |
<0.0001 |
|
| |||||
| Lp(a) (mg/dL) | 32 [IQR: 15–50.3] |
17.55 [IQR: 12.8–53.5] |
17.85 [IQR: 15.5–38.20] |
17.45 [IQR: 10.95–22.0] |
0.003 |
|
| |||||
| Excess Lp(a) percent (%) | N: 25 (52%) | N: 21 (42%) | N = 16 (28%) | N: 6 (12%) | <0.0001 |
|
| |||||
| BMI (kg/m2) | 26.64 ± 2.02 | 26.36 ± 2.22 | 25.58 ± 2.72 | 24.9 ± 2.52 | <0.0001 |
|
| |||||
| HOMA | 1.76 ± 0.54 | 1.68 ± 0.58 | 1.73 ± 0.55 | 1.59 ± 0.62 | 0.22 |
Normally distributed values are indicated as mean ± SD; nonnormaly distributed values are indicated as median and interquartile ranges.
TSH: thyroid stimulating hormone, FT4: free thyroxin, Total-C: total cholesterol, TG: triglyceride, HDL: high density lipoprotein, LDL: low density lipoprotein, Lp(a): lipoprotein(a), and BMI: body mass index; HOMA for insulin resistance index.
P values are the differences of total Hashimoto groups and control group.